Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Ikonisys has started a clinical trial evaluating its breakthrough test for early detection of chromosomal abnormality trisomy 21.
Subscribe to our email newsletter
The trial aims to validate the use of circulating fetal cells in early prenatal detection of Down syndrome within the first trimester of pregnancy. Ikonisys expects this solution to be the first in a suite of non-invasive cell-based fetal tests.
Petros Tsipouras, CEO and chairman of Ikonisys, said: “With this clinical trial, we seek to prove a novel test for early non-invasive, detection of Down syndrome that eliminates the need for repeat testing and offers women the reassurance, certainty and accuracy that they need to make better, more informed decisions.”